Post-Transplantation B Cell Function in Different Molecular Types of SCID
- 644 Downloads
Severe combined immunodeficiency (SCID) is a syndrome of diverse genetic cause characterized by profound deficiencies of T, B and sometimes NK cell function. Non-ablative HLA-identical or rigorously T cell-depleted haploidentical parental bone marrow transplantation (BMT) results in thymus-dependent genetically donor T cell development in the recipients, leading to a high rate of long-term survival. However, the development of B cell function has been more problematic. We report here results of analyses of B cell function in 125 SCID recipients prior to and long-term after non-ablative BMT, according to their molecular type.
Studies included blood immunoglobulin measurements; antibody titers to standard vaccines, blood group antigens and bacteriophage Φ X 174; flow cytometry to examine for markers of immaturity, memory, switched memory B cells and BAFF receptor expression; B cell chimerism; B cell spectratyping; and B cell proliferation.
The results showed that B cell chimerism was not required for normal B cell function in IL7Rα-Def, ADA-Def and CD3-Def SCIDs. In X-linked-SCID, Jak3-Def SCID and those with V-D-J recombination defects, donor B cell chimerism was necessary for B cell function to develop.
The most important factor determining whether B cell function develops in SCID T cell chimeras is the underlying molecular defect. In some types, host B cells function normally. In those molecular types where host B cell function did not develop, donor B cell chimerism was necessary to achieve B cell function. 236 words
KeywordsB cell function B cell chimerism bone marrow transplantation severe combined immunodeficiency molecular type memory B cells
We thank the patients and their families, the physicians who referred them and who cared for them, Dr. A. Yu and D. Ozaki for their help with the BCR spectratype data, the members of the Duke University DNA Analysis Facility and the Duke Comprehensive Cancer Center Flow Cytometry Facility. This research was supported by National Institutes of Health grants AI47605 and AI042951, and in part by the Duke RBL (AI58607), and the Duke CTR (AI51445).
Disclosures: None of the authors has any commercial affiliations or consultancies to disclose.
- 6.Hirschhorn R. Immunodeficiency diseases due to deficiency of adenosine deaminase. In: Ochs HD, Smith CIE, Puck JM, editors. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. 1st ed. New York and Oxford: Oxford University Press; 1999. p. 121–39.Google Scholar
- 10.Roberts JL, Buckley RH, Luo B, Pei J, Lapidus A, Peri S, et al. CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proc Natl Acad Sci U S A. 2012;109:10456–61.Google Scholar
- 18.Moen RC, Horowitz SD, Sondel PM, Borcherding WR, Trigg ME, Billing R, et al. Immunologic reconstitution after haploidentical bone marrow transplantation for immune deficiency disorders: treatment of bone marrow cells with monoclonal antibody CT-2 and complement. Blood. 1987;70:664–9.PubMedGoogle Scholar
- 21.Haddad E, Deist FL, Aucouturier P, Cavazzana-Calvo M, Blanche S, Basile GD, et al. Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: a single-center study of 22 patients. Blood. 1999;94(8):2923–30.PubMedGoogle Scholar
- 22.van Leeuwen JE, van Tol MJ, Joosten AM, Schellekens PT, van den Bergh RL, Waaijer JL, et al. Relationship between patterns of engraftment in peripheral blood and immune reconstitution after allogeneic bone marrow transplantation for (severe) combined immunodeficiency. Blood. 1994;84:3936–47.PubMedGoogle Scholar
- 26.Patel NC, Chinen J, Rosenblatt HM, Hanson IC, Brown BS, Paul ME, et al. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. J Allergy Clin Immunol. 2008;122(6):1185–93.PubMedCrossRefGoogle Scholar
- 28.Slatter MA, Brigham K, Dickinson AM, Harvey HL, Barge D, Jackson A, et al. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J Allergy Clin Immunol. 2007;121:361–7.PubMedCrossRefGoogle Scholar
- 29.Dvorak CC, Hung GY, Horn B, Dunn E, Oon CY, Cowan MJ. Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2008;14(10):1125–33.PubMedCrossRefGoogle Scholar
- 31.Buckley RH. B cell function in severe combined immunodeficiency after stem cell or gene therapy: A review. J Allergy Clin Immunol. 2010;125:790–7.Google Scholar
- 37.Van Den Berg H, Vossen JM, van den Bergh RL, Bayer J, van Tol MJD. Detection of Y chromosome by in situ hybridization in combination with membrane antigens by two-color immunofluorescence. Lab Investig. 1994;64:623–8.Google Scholar
- 42.Tweeddale M, Lim B, Jamal N, Minden M, Messner HA. J Cell Biochem. 1985;117(Suppl 9A). Abstract.Google Scholar
- 44.Bonferroni CE. Il Calcolo Delle Assicurazioni su Gruppi di Teste. Studi in Onore del Professore Salvatore Ortu Carboni. Rome, Italy: 1935. p. 13–60.Google Scholar